Therefore, previous randomized clinical trials involving Asian advanced NSCLC patients with EGFR mutation have demonstrated that bevacizumab plus erlotinib offered a higher efficacy, in terms of PFS, compared to erlotinib treatment alone. Here, EGFR is linked to non-small cell lung carcinoma.